The MONARCH 2 study: FASLODEX in combination with VerzenioTM (abemaciclib)

FASLODEX is a prescription medicine used to treat women with HR-positive, HER2-negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), in combination with palbociclib or abemaciclib in women whose disease has progressed after endocrine therapy.

MONARCH 2 studied FASLODEX with Verzenio

Drugs like FASLODEX are tested in clinical studies to see how well they work before they are approved for use. These studies are also known as clinical trials.

MONARCH 2 is a study that examined how well FASLODEX with VerzenioTM (abemaciclib) worked vs FASLODEX and placebo in HR-positive, HER2-negative advanced or metastatic breast cancer, and examined what types of side effects women in the study experienced.

Based on the results of MONARCH 2, FASLODEX with Verzenio can be used to treat HR-positive, HER2-negative advanced or metastatic breast cancer that has spread after endocrine therapy. Your advanced or metastatic breast cancer therapy is a complex choice influenced by many factors—talk to your doctor about what the MONARCH 2 study may mean for this decision.

Understanding this study may help you discuss FASLODEX with your doctor. FASLODEX with Verzenio may be an appropriate choice to treat HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression, if the cancer has spread after endocrine therapy.

669-women

Patients in the study

MONARCH 2 included 669 women who had either been through menopause or had been given medication that began menopause. These women had HR-positive, HER2-negative advanced or metastatic breast cancer. Their cancer had spread while receiving prior endocrine therapy, meaning that they were endocrine therapy resistant. Talk to your doctor about what endocrine therapy resistance may mean for your treatment.

where cancer spread 2-01

Where their cancer spread

Women in the MONARCH 2 study had cancer that spread to the organs, such as liver or lungs (56% of women), or to only the bones (27% of women).

prior_treatment-01

Prior treatment for metastatic disease

Over half (59.2%) of patients received this treatment as their first endocrine therapy for advanced or metastatic breast cancer, while over one-third of patients (38.3%) received it as their second or later.

MONARCH 2 study results

FASLODEX in combination with Verzenio significantly extended the length of time during and after treatment that patients lived without their cancer getting worse, compared with FASLODEX and placebo. This measure, known as progression-free survival time, is one way to see how well a treatment works. Progression-free survival can be displayed as the middle of a range of months, also known as the median.

Median progression-free survival time for FASLODEX with Verzenio vs FASLODEX and placebo was 16.4 months vs 9.3 months, respectively, a 76% improvement.

These results were shown to be statistically significant, meaning that it is highly likely that the results are related to treatment rather than something else.

HER2=human epidermal growth factor receptor 2; HR=hormone receptor.

16.4 month’s median progression-free survival for FASLODEX with abemaciclib
9.3 month’s median progression-free survival for FASLODEX with placebo.
16.4_months_mobile
9.3_months_mobile

IMPORTANT SAFETY INFORMATION

    You should not receive FASLODEX if you have had an allergic reaction to fulvestrant or any of the ingredients in FASLODEX. Talk to your health care provider if you experience symptoms of an allergic reaction to FASLODEX, which may include itching or hives; swelling of your face, lips, tongue, or throat; and trouble breathing.

    Before receiving FASLODEX, tell your health care provider about all of your medical conditions, including if you:

  • Have a low level of platelets in your blood or bleed easily. Especially tell your health care provider if you take a blood thinner medicine (anticoagulant)
  • Have liver problems
  • Are pregnant or plan to become pregnant, because FASLODEX can harm your unborn baby. Women who are able to become pregnant should use effective birth control during treatment with FASLODEX and for 1 year after the final dose. Tell your health care provider right away if you become pregnant or think you are pregnant while on FASLODEX
  • Are breastfeeding or plan to breastfeed. It is not known if FASLODEX passes into breast milk. Do not breastfeed during treatment with FASLODEX and for 1 year after the final dose. Talk to your health care provider about the best way to feed your baby during this time

Tell your health care provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. FASLODEX may affect the way other medicines work, and other medicines may affect how FASLODEX works.

FASLODEX is administered by your health care provider as an injection into the muscle of each buttock. Your health care provider may change your dose of FASLODEX if needed.

FASLODEX may cause injection site–related nerve damage. Call your health care provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness, tingling, or weakness.

Common side effects of FASLODEX include injection site pain; nausea; muscle, joint, and bone pain; headache; tiredness; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath; constipation; increased liver enzymes; and diarrhea.

Tell your health care provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your health care provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088.

Approved Uses for FASLODEX

FASLODEX is a prescription medicine used to treat women with:

  • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, who have gone through menopause and have not been previously treated with endocrine therapy
  • HR-positive advanced breast cancer, who have gone through menopause and whose disease has progressed after endocrine therapy
  • HR-positive, HER2‐negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), in combination with palbociclib or abemaciclib, in women whose disease has progressed after endocrine therapy

When FASLODEX is used in combination with palbociclib, please also see the palbociclib Patient Information.

When FASLODEX is used in combination with abemaciclib, please also see the abemaciclib Patient Information.

It is not known if FASLODEX is safe and effective in children or in people with severe liver problems.

Please see FASLODEX Prescribing Information with Patient Information (Medication Guide).

 
 
Read More

IMPORTANT SAFETY INFORMATION

    You should not receive FASLODEX if you have had an allergic reaction to fulvestrant or any of the ingredients in FASLODEX. Talk to your health care provider if you experience symptoms of an allergic reaction to FASLODEX, which may include itching or hives; swelling of your face, lips, tongue, or throat; and trouble breathing.

    Before receiving FASLODEX, tell your health care provider about all of your medical conditions, including if you:

  • Have a low level of platelets in your blood or bleed easily. Especially tell your health care provider if you take a blood thinner medicine (anticoagulant)
  • Have liver problems
  • Are pregnant or plan to become pregnant, because FASLODEX can harm your unborn baby. Women who are able to become pregnant should use effective birth control during treatment with FASLODEX and for 1 year after the final dose. Tell your health care provider right away if you become pregnant or think you are pregnant while on FASLODEX
  • Are breastfeeding or plan to breastfeed. It is not known if FASLODEX passes into breast milk. Do not breastfeed during treatment with FASLODEX and for 1 year after the final dose. Talk to your health care provider about the best way to feed your baby during this time

Tell your health care provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. FASLODEX may affect the way other medicines work, and other medicines may affect how FASLODEX works.

FASLODEX is administered by your health care provider as an injection into the muscle of each buttock. Your health care provider may change your dose of FASLODEX if needed.

FASLODEX may cause injection site–related nerve damage. Call your health care provider if you develop any of the following symptoms in your legs following a FASLODEX injection: numbness, tingling, or weakness.

Common side effects of FASLODEX include injection site pain; nausea; muscle, joint, and bone pain; headache; tiredness; hot flashes; vomiting; loss of appetite; weakness; cough; shortness of breath; constipation; increased liver enzymes; and diarrhea.

Tell your health care provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with FASLODEX. For more information, ask your health care provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-10881-800-FDA-1088.

Approved Uses for FASLODEX

FASLODEX is a prescription medicine used to treat women with:

  • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, who have gone through menopause and have not been previously treated with endocrine therapy
  • HR-positive advanced breast cancer, who have gone through menopause and whose disease has progressed after endocrine therapy
  • HR-positive, HER2‐negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), in combination with palbociclib or abemaciclib, in women whose disease has progressed after endocrine therapy

When FASLODEX is used in combination with palbociclib, please also see the palbociclib Patient Information.

When FASLODEX is used in combination with abemaciclib, please also see the abemaciclib Patient Information.

It is not known if FASLODEX is safe and effective in children or in people with severe liver problems.

Please see FASLODEX Prescribing Information with Patient Information (Medication Guide).